Article
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58, and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis.
Expert opinion on biological therapy - 1 Feb 2021
Morelli Martina, Galluzzo Marco, Madonna Stefania, Scarponi Claudia, Scaglione Giovanni Luca, Galluccio Tiziana, Andreani Marco, Pallotta Sabatino, Girolomoni Giampiero, Bianchi Luca, Talamonti Marina, Albanesi Cristina
Abstract excerpt
Objective: Our pharmacogenomic study evaluated the influence of the presence/absence of genetic variants of psoriasis-risk loci on the clinical response to secukinumab. Differences in the single-nucleotide polymorphism (SNP) pattern characterizing HLA-Cw6+ or HLA-Cw6- patient subpopulations, showing high or low responses to secukinumab, were also analyzed. Methods: 417 SNPs were analyzed by Next-Generation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.